PTCT - PTC Therapeutics, Inc.
| Previous Close | 34.61 |
| Open | 34.75 |
| Bid | 30.00 x 900 |
| Ask | 48.00 x 900 |
| Day's Range | 34.01 - 34.98 |
| 52 Week Range | 21.63 - 52.95 |
| Volume | 501,431 |
| Avg. Volume | 697,130 |
| Market Cap | 1.738B |
| Beta (3Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings Date | Mar 4, 2019 - Mar 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.43 |
- PR Newswire•15 days ago
PTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house
SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical ...
- PR Newswire•15 days ago
PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference
SOUTH PLAINFIELD, N.J., Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today provided a corporate update, which will be detailed as part of the company's presentation at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8th at 5:00 p.m. PT. The presentation will be webcast live on the Events and Presentations page under the investors' section of PTC Therapeutics' website at www.ptcbio.com. PTC plans to submit a BLA with the FDA followed by an MAA in Europe for the AADC deficiency gene therapy program in 2H 2019 with expected launch in 2020.
- Insider Monkey•18 days ago
Praesidium Investment Management’s Return, AUM, and Holdings
An activist hedge fund, Praesidium Investment Management, was founded a decade ago by experienced investors, Kevin Oram and Peter Uddo. Prior to co-founding Praesidium Investment Management, Kevin Oram, a Chartered Financial Analyst, was employed at Sanford C. Bernstein, where he worked as a Senior Analyst, Senior Vice-President, and was in charge of investments in the […]
- PR Newswire•19 days ago
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, ...
- PR Newswire•last month
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., Dec. 20, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on December 17, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). All stock option awards have an exercise price of $32.23 per share, the closing price of PTC's common stock on December 17, 2018, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates.
- PR Newswire•last month
PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments
SOUTH PLAINFIELD, N.J., Dec. 18, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the appointment of Emma Reeve and Stephanie Okey to the Company's Board of Directors. Ms. Reeve currently serves as the Chief Financial Officer of Constellation Pharmaceuticals, Inc., a publicly-traded company, and will enhance the financial expertise of the Board. Ms. Okey most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Disease Business Unit at Genzyme and brings decades of experience launching and commercializing rare and orphan disease products.
- Zacks•last month
Roche's SMA Candidate Risdiplam Gets PRIME Designation in EU
Roche's (RHHBY) investigational oral medicine risdiplam gets PRIME designation for the treatment of SMA.
Zacks•last monthShould You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
Sector ETF report for PTH
- Simply Wall St.•last month
Is PTC Therapeutics, Inc.’s (NASDAQ:PTCT) CEO Paid Enough Relative To Peers?
Stuart Peltz became the CEO of PTC Therapeutics, Inc. (NASDAQ:PTCT) in 1998. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a Read More...
- Insider Monkey•last month
Ghost Tree Capital’s AUM, Returns and Holdings
David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]
- Insider Monkey•last month
Hedge Funds Are Buying PTC Therapeutics, Inc. (PTCT)
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- PR Newswire•last month
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., Dec. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on December 4, 2018 it approved non-statutory stock options to purchase an aggregate of 48,750 shares of its common stock to 10 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on December 4, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). All stock option awards have an exercise price of $34.35 per share, the closing price of PTC's common stock on December 4, 2018, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PTCT earnings conference call or presentation 5-Nov-18 9:30pm GMT
Q3 2018 PTC Therapeutics Inc Earnings Call
- PR Newswire•2 months ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., Nov. 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on November 13, 2018 it approved non-statutory stock options to purchase an aggregate of 75,200 shares of its common stock to 19 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on November 13, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Fifteen of the stock option awards have an exercise price of $31.96 per share, the closing price of PTC's common stock on November 13, 2018, the date of the grant.
- Zacks•2 months ago
New Strong Sell Stocks for November 9th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
- Motley Fool•2 months ago
Here's Why PTC Therapeutics Dropped 18% in October
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
- Zacks•3 months ago
PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -135.00% and -21.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
PTC Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of $1.06. Losses, adjusted for asset impairment costs, came to 94 cents per share. The biopharmaceutical company ...
Insider Monkey•3 months agoAmazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
Although November 6 is very important to the stock market because it’s election day in the United States, traders are also paying attention to several equities that are trending for various reasons. Without further elaboration, let’s dive in and see why the spotlight is shining on Amazon.com Inc. (NASDAQ:AMZN), The Kraft Heinz Company (NASDAQ:KHC), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), PTC […]
- PR Newswire•3 months ago
PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update
-Completed acquisition of Agilis Biotherapeutics gene therapy platform- -In-licensed two rare disease therapies from Akcea Therapeutics- SOUTH PLAINFIELD, N.J. , Nov. 5, 2018 /PRNewswire/ -- PTC Therapeutics, ...
- PR Newswire•3 months ago
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J. , Oct. 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 27 th Annual Healthcare ...
- Zacks•3 months ago
PTC Therapeutics (PTCT) Q3 Earnings Preview: What to Watch Ahead of the Release
PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•3 months ago
How Does PTC Therapeutics Inc (NASDAQ:PTCT) Affect Your Portfolio Volatility?
Anyone researching PTC Therapeutics Inc (NASDAQ:PTCT) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...
- PR Newswire•3 months ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J., Oct. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on October 17, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Eight of the stock option awards have an exercise price of $39.73 per share, the closing price of PTC's common stock on October 17, 2018, the date of the grant.
